Abstract
T cells play a role in the initiation and perpetuation of tissue inflammation that can lead to tissue destruction. With the discovery of a number of T helper subsets and their potential plasticity during disease it became clear that the T cell behaviour in autoimmune diseases is much more complex than the first Th1/Th2 concept. From experimental autoimmune arthritis models it became clear that the IL-23/IL-17 immune pathway is critical in the development of autoimmune arthritis and IL-17A has been recognized to be a key cytokine involved in initiation and perpetuation of chronic destructive arthritis. Functional studies using T cells and stromal cells from patients with RA revealed improvement of anti-TNF effects when combined with agents neutralizing IL-17A or agents suppressing Th17 cytokines production. Clinic trials will be needed to test whether these data from experimental settings can be translated to human arthritis.
Different approaches are available or under investigation to target: (1) pathogenic T cell activity by inhibiting RORc or STAT3 or the costimulator pathway by CTLA4-Ig; (2) Th17 cytokine production by anti-IL-17A, anti-IL-22, or combination of anti-IL-17A/anti-TNF approaches; (3) Th17 polarization by neutralizing IL-23 using an anti-IL-23 specific antibody, IL-12/IL-23 by an anti-p40 antibody, or the IL-6 signaling pathway; (4) Th17 migration by interfering the CCR6-CCL20 interaction. The challenge is to bring the best to the clinic to further improve current therapy for patients with RA and to reach stable remission or even prevent the development of this disabling disease.
Keywords: T cells, IL-17, Th17, cytokines, transcription factors, arthritis, auto-immune disease, IL-23.
Current Pharmaceutical Design
Title:Role of T Lymphocytes in the Development of Rheumatoid Arthritis. Implications for Treatment
Volume: 21 Issue: 2
Author(s): Erik Lubberts
Affiliation:
Keywords: T cells, IL-17, Th17, cytokines, transcription factors, arthritis, auto-immune disease, IL-23.
Abstract: T cells play a role in the initiation and perpetuation of tissue inflammation that can lead to tissue destruction. With the discovery of a number of T helper subsets and their potential plasticity during disease it became clear that the T cell behaviour in autoimmune diseases is much more complex than the first Th1/Th2 concept. From experimental autoimmune arthritis models it became clear that the IL-23/IL-17 immune pathway is critical in the development of autoimmune arthritis and IL-17A has been recognized to be a key cytokine involved in initiation and perpetuation of chronic destructive arthritis. Functional studies using T cells and stromal cells from patients with RA revealed improvement of anti-TNF effects when combined with agents neutralizing IL-17A or agents suppressing Th17 cytokines production. Clinic trials will be needed to test whether these data from experimental settings can be translated to human arthritis.
Different approaches are available or under investigation to target: (1) pathogenic T cell activity by inhibiting RORc or STAT3 or the costimulator pathway by CTLA4-Ig; (2) Th17 cytokine production by anti-IL-17A, anti-IL-22, or combination of anti-IL-17A/anti-TNF approaches; (3) Th17 polarization by neutralizing IL-23 using an anti-IL-23 specific antibody, IL-12/IL-23 by an anti-p40 antibody, or the IL-6 signaling pathway; (4) Th17 migration by interfering the CCR6-CCL20 interaction. The challenge is to bring the best to the clinic to further improve current therapy for patients with RA and to reach stable remission or even prevent the development of this disabling disease.
Export Options
About this article
Cite this article as:
Lubberts Erik, Role of T Lymphocytes in the Development of Rheumatoid Arthritis. Implications for Treatment, Current Pharmaceutical Design 2015; 21 (2) . https://dx.doi.org/10.2174/1381612820666140825122247
DOI https://dx.doi.org/10.2174/1381612820666140825122247 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lysosomal Molecules are Up-Regulated in the Articular Cartilage Explants Subjected to Oxidative Stress and in the Cartilage from an Osteoarthritis-Induced Rat Model
Recent Patents on Biomarkers Knowing is Half the Battle: Targeting Virulence Factors of Group A Streptococcus for Vaccine and Therapeutics
Current Drug Targets Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Structural Requirements of Heparin and Related Molecules to Exert a Multitude of Anti-Inflammatory Activities
Mini-Reviews in Medicinal Chemistry A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology Current Status and Future Prospects for Research on Tyrosine Sulfation
Current Pharmaceutical Biotechnology Arthropathy in Patients with CREST Variant Scleroderma
Current Rheumatology Reviews Transglutaminase-Catalyzed Reactions Responsible for the Pathogenesis ofCeliac Disease and Neurodegenerative Diseases: From Basic Biochemistry to Clinic
Current Medicinal Chemistry Mechanisms of Improvement of Left Ventricular Function by Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Infusion in Very Old Patients with Coronary Chronic Total Occlusion
Current Pharmaceutical Design Plasma Protein Binding in Drug Discovery and Development
Combinatorial Chemistry & High Throughput Screening Chinese Herbs as Immunomodulators and Potential Disease-Modifying Antirheumatic Drugs in Autoimmune Disorders
Current Drug Metabolism The Inverse Relationship Between Cancer and Alzheimer's Disease: A Possible Mechanism
Current Alzheimer Research Chemokine Receptor Inhibitors as a Novel Option in Treatment of Asthma
Current Drug Targets - Inflammation & Allergy Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases
Current Pharmaceutical Design Multiple Sclerosis: Current and Future Treatment Options
Endocrine, Metabolic & Immune Disorders - Drug Targets Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Subtype Selectivity in Phosphodiesterase 4 (PDE4): A Bottleneck in Rational Drug Design
Current Pharmaceutical Design G Protein-Coupled Receptor Kinase 2 - a Feedback Regulator of Gq Pathway Signalling
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery